Previous 10 | Next 10 |
Dova Pharmaceuticals (NASDAQ: DOVA ) +39% on being acquired by Sobi. More news on: Dova Pharmaceuticals, Inc., Bed Bath & Beyond Inc., ImmunoGen, Inc., Stocks on the move, Read more ...
FORWARD II Triplet Combination Demonstrates Encouraging Anti-Tumor Activity Preliminary Findings Support Ongoing Study in Platinum-Sensitive Patients ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, t...
FORWARD I Did Not Meet Primary Endpoint of Progression-Free Survival; Promising Efficacy Results Seen in Folate Receptor Alpha (FRα) High Patients Favorable Tolerability and Differentiated Safety Profile Observed with Mirvetuximab Monotherapy Compared to Chemotherapy Explor...
Sell-side analysts comment on cancer therapy data to be presented at ESMO in Barcelona starting today. More news on: Seattle Genetics, Inc., Clovis Oncology, Inc., AstraZeneca PLC, Healthcare stocks news, Read more ...
Conference Call to be Held at 8 a.m. ET on Monday, September 30 ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that full data and additional exploratory analyses from the Phase 3 FORWARD ...
The NASDAQ Biotechnology Index (INDEXNASDAQ: NBI ) rose last week from 3,260.87 points on Monday (August 5) to settle at 3,294.97 points as of 1:26 p.m. EDT on Friday (August 9). On Wednesday (August 7), Rhythm Pharmaceuticals (NASDAQ: RYTM ) revealed positive results from its Phase 3 clin...
August 6, 2019 Palm Beach, FL –August 6, 2019 – According to an industry report , the global oncology/cancer drugs market (which was valued at $97,401 Million in 2017) is estimated to reach at $176,509 Million by 2025, registering a CAGR of 7.6% from 2018 to 2025....
Immunogen, Inc. (IMGN) Q2 2019 Results Earnings Conference Call August 2, 2019 08:00 AM ET Company Participants Courtney O'Konek - Senior Director, Investor Relations and Corporate Communications Mark Enyedy - President and Chief Executive Officer Anna Berkenblit - Chief Medic...
ImmunoGen ( IMGN ) Q2 results : Revenues: $15.5M (+66.7%); Non-cash royalty revenue: $10.4M (+44.4%); License and milestone fees: $5.1M ; R&D support: $0.05M (-87.5%). More news on: ImmunoGen, Inc., Healthcare stocks news, Earnings news and commentary, Read more ...
ImmunoGen (NASDAQ: IMGN ): Q2 GAAP EPS of -$0.29 beats by $0.04 . More news on: ImmunoGen, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Klepierre (KLPEF) is expected to report for Q4 2023 comScore Inc. (SCOR) is expected to report $0.8 for Q4 2023 Universal Stainless & Alloy Products Inc. (USAP) is expected to report for Q4 2023 FAT Brands Inc. (FAT) is expected to report $-1.55 for Q4 2023 Jet.AI Inc. (JTAI) ...
AbbVie Completes Acquisition of ImmunoGen PR Newswire Adds flagship antibody-drug conjugate (ADC) ELAHERE ® (mirvetuximab soravtansine-gynx) for folate receptor-alpha (FRα) positive platinum-resistant ovarian cancer (PROC) to AbbVie's portfolio ...
2024-02-10 09:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...